arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BioCardia, Inc.

BCDA
$0.88 ▼ -0.04 (-3.84%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
28 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BioCardia, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $10.6M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -47.5% ↘
FCF / Share $-0.14 ↗
Trailing P/E —
Price / Book 4.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-2.26M
↑ +16.7% —
Operating Margin Operating profit as % of sales
-256.3%
↑ +22.3% —
FCF / Share Free cash flow per share
$-0.14
↑ +6.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -730.7% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.90x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters